GRAIL Inc Partners with Samsung for $110M Investment

The latest update is out from GRAIL Inc ( (GRAL) ).

On October 16, 2025, GRAIL, Inc. entered into a stock purchase agreement with Samsung C&T Corporation and Samsung Electronics to issue and sell shares worth $110 million in a private placement. This strategic collaboration aims to commercialize GRAIL’s Galleri multi-cancer early detection test in South Korea, with potential expansion to Japan and Singapore. The agreement includes conditions such as regulatory approvals and the execution of business and strategic collaboration agreements by early 2026. This partnership is expected to strengthen GRAIL’s market position in Asia and provide financial support for its commercialization and reimbursement efforts.

The most recent analyst rating on (GRAL) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on GRAIL Inc stock, see the GRAL Stock Forecast page.

Spark’s Take on GRAL Stock

According to Spark, TipRanks’ AI Analyst, GRAL is a Neutral.

GRAIL Inc.’s overall stock score reflects strong revenue growth and positive developments from the earnings call, tempered by significant profitability challenges and poor valuation metrics. The technical analysis indicates bearish momentum, further impacting the score.

To see Spark’s full report on GRAL stock, click here.

More about GRAIL Inc

GRAIL is a healthcare company focused on early cancer detection using advanced technologies like next-generation sequencing and machine learning. Its flagship product, the Galleri test, is designed to detect multiple types of cancer early, potentially improving treatment outcomes. The company is headquartered in Menlo Park, CA, with operations in North Carolina, Washington, D.C., and the UK.

Average Trading Volume: 908,803

Technical Sentiment Signal: Buy

Current Market Cap: $2.72B

See more data about GRAL stock on TipRanks’ Stock Analysis page.